A Lewy body is an abnormal inclusion within the cytoplasm of a nerve cell, characterized by accumulated alpha-synuclein and other cellular material. Lewy bodies are characteristic pathological findings in Parkinson’s disease and dementia with Lewy bodies, although they can also occur in people without a recognized neurological disorder. They are microscopic tissue structures, not a disease or clinical diagnosis in themselves.
Structure and composition
Lewy bodies vary in appearance according to their location and the method used to examine them. With conventional tissue staining, a classical brainstem Lewy body appears as a rounded, pink-staining inclusion with a dense central region and a paler surrounding halo. Cortical Lewy bodies are often less sharply defined and may lack this conspicuous core-and-halo appearance.
Their defining molecular component is aggregated alpha-synuclein, a protein normally found especially at presynaptic nerve terminals, where it participates in processes involving synaptic vesicles. Within Lewy pathology, alpha-synuclein is abnormally accumulated and frequently chemically modified, including by phosphorylation.
Lewy bodies also contain other proteins, lipids, membrane fragments, and cellular organelles. These include ubiquitin and proteins involved in cellular disposal pathways. Ultrastructural studies have revealed crowded membranes, vesicles, and abnormal mitochondria, showing that Lewy bodies are more complex than deposits of a single protein.
Related elongated alpha-synuclein-positive inclusions in neuronal processes are called Lewy neurites. The expression Lewy pathology commonly encompasses both Lewy bodies and Lewy neurites.
Distribution in the nervous system
Lewy pathology can occur in the brainstem, limbic regions, cerebral cortex, and parts of the peripheral and autonomic nervous systems. Its distribution differs among individuals and disease presentations.
In Parkinson’s disease, Lewy pathology often accompanies the loss of dopamine-producing neurons in the substantia nigra. This neuronal loss contributes to the characteristic motor syndrome. In dementia with Lewy bodies, pathology frequently involves limbic and cortical regions, although brainstem structures may also be affected.
Neuropathologists describe patterns such as brainstem-predominant, limbic, and diffuse neocortical Lewy pathology. These categories help characterize tissue findings, but the relationship between anatomical distribution and clinical symptoms is not exact.
One influential framework, commonly called Braak staging of Parkinson’s disease pathology, describes an ordered distribution progressing from lower brainstem and olfactory structures toward more extensive brain involvement. It fits some cases but not all; it is not a universal sequence through which every affected person passes.
Relationship to disease
Parkinson’s disease and dementia with Lewy bodies belong to the synucleinopathies, disorders characterized by abnormal alpha-synuclein accumulation.
The main clinical associations are:
- Parkinson’s disease: commonly associated with neuronal loss in the substantia nigra and Lewy pathology, although some genetically defined forms can lack typical Lewy bodies.
- Dementia with Lewy bodies: a dementia syndrome associated with Lewy pathology and features that can include cognitive fluctuations, recurrent visual hallucinations, parkinsonism, and REM sleep behavior disorder.
- Parkinson’s disease dementia: dementia developing in the setting of established Parkinson’s disease, often with widespread Lewy pathology.
Lewy pathology can coexist with Alzheimer’s disease pathology and other changes in the brain. Such mixed findings complicate attempts to attribute symptoms to one pathological process.
Lewy bodies are also sometimes found at autopsy in people who had no recognized Parkinson’s disease or dementia. This is often described as incidental Lewy body disease. Their presence alone therefore does not establish the symptoms a person experienced or would eventually have developed.
Not all synucleinopathies are primarily Lewy body disorders. In multiple system atrophy, the characteristic alpha-synuclein inclusions occur mainly in oligodendrocytes rather than as neuronal Lewy bodies.
Formation and biological significance
Lewy body formation is linked to abnormal protein folding, aggregation, and disturbances in cellular protein handling. Alpha-synuclein can assemble into smaller aggregates and larger fibrillar structures. Processes involving lysosomes, protein degradation, membrane trafficking, and mitochondrial function are implicated in the associated cellular pathology.
The precise role of a mature Lewy body remains unresolved. Its presence is evidence of an abnormal cellular process, but it does not establish that the visible inclusion itself is the principal cause of neuronal death. Smaller alpha-synuclein assemblies, disrupted membranes, and impaired cellular functions may also contribute. Inclusion formation may involve both damaging processes and attempts by the cell to sequester abnormal material.
Experiments show that abnormal alpha-synuclein assemblies can promote further aggregation and can move between cells in model systems. These findings inform research on how pathology spreads, but do not establish an identical progression in every human case or imply ordinary person-to-person contagiousness.
Detection and interpretation
Lewy bodies are identified by microscopic examination of tissue, most commonly during postmortem neuropathological assessment. Immunohistochemistry using an antibody against alpha-synuclein is more sensitive for detecting Lewy pathology than conventional staining alone and can reveal Lewy neurites as well as cell-body inclusions.
Routine brain imaging does not directly show individual Lewy bodies. Tests that detect abnormal alpha-synuclein or its seeding activity can provide evidence relevant to an underlying synucleinopathy, but such results are not equivalent to directly observing a Lewy body. Clinical syndromes and pathological findings remain related but distinct levels of description.
History
Lewy bodies are named after the neurologist Friedrich Heinrich Lewy, who described the inclusions in 1912 while investigating Parkinson’s disease. Recognition of more widespread cortical Lewy pathology later helped establish its importance in dementia. In 1997, alpha-synuclein was identified as a major component of Lewy bodies, linking the microscopic lesion to a molecular framework for studying synucleinopathies.